Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Down’s Syndrome

This article was originally published in The Gray Sheet

Executive Summary

First-semester combination screening is better than second-semester quadruple screening for identifying fetal Down's Syndrome, according to the results of the 38,167 patient FASTER trial, published in the Nov. 10 New England Journal of Medicine by Fergal Malone, MD, Columbia University, et al. "When there is an appropriate quality control for measurement of nuchal translucency [the space in the tissue at the back of the fetus' developing neck], first-trimester combined screening is a powerful tool for the detection of Down's Syndrome," the authors conclude...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT022891

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel